Neubewertung nach Fristablauf: Myelofibrose
G-BA action
final resolution
2025-08-21
Evidence-checked summary
The G-BA issued a final resolution on 2025-08-21. The official page states that it took effect as follows: 21.08.2025. The page lists Arzneimittel-Richtlinie, Anlage XII: Nutzenbewertung nach § 35a SGB V as the normative target.
This is the latest validated public action attached to this case. It is separate from the IQWiG assessment result.
Official case record
No inferred stages
Consultation record
2025-07-07
48 parsed turns
Oral hearing: Fedratinib (Neubewertung nach Fristablauf: Myelofibrose)
Official Wortprotokoll · 10 pages
IQWiG comparison
IQWiG assessment findings and the later G-BA action are separate records. Open both to compare them.
No IQWiG assessment reference is present on the validated official case page. This is an explicit absence, not a broken graph link.
G-BA decisions
2025-08-21
final resolution
The G-BA issued a final resolution on 2025-08-21. The official page states that it took effect as follows: 21.08.2025. The page lists Arzneimittel-Richtlinie, Anlage XII: Nutzenbewertung nach § 35a SGB V as the normative target.
4 official documents · 3 cited claims
Official sources